Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 26, 2022; 10(12): 3849-3855
Published online Apr 26, 2022. doi: 10.12998/wjcc.v10.i12.3849
Combined targeted therapy and immunotherapy in anaplastic thyroid carcinoma with distant metastasis: A case report
Dong-Xu Ma, Xiu-Ping Ding, Chi Zhang, Peng Shi
Dong-Xu Ma, Chi Zhang, Peng Shi, Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong Province, China
Dong-Xu Ma, Department of Cheeloo College of Medicine, Shandong University, Jinan 250021, Shandong Province, China
Xiu-Ping Ding, Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, Shandong Province, China
Author contributions: Ma DX wrote this paper; Shi P joined the surgery and revised the paper; Zhang C collect the information and follow up of the patient; Ding XP joined the targeted therapy and immunotherapy.
Informed consent statement: Informed consent was obtained from the patient for this case report and accompanying images.
Conflict-of-interest statement: All authors have no relevant conflicts of interest with the manuscript.
CARE Checklist (2016) statement: The authors adopted the guidelines of the CARE checklist (2016) during the preparation of this manuscript and have compared the modifications.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Peng Shi, PhD, Chief Doctor, Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong University, No. 324 Jing 5 Road, Jinan 250021, Shandong Province, China. shipengwmm@126.com
Received: July 26, 2021
Peer-review started: July 26, 2021
First decision: October 22, 2021
Revised: December 2, 2021
Accepted: March 6, 2022
Article in press: March 6, 2022
Published online: April 26, 2022
Processing time: 268 Days and 23.3 Hours
Core Tip

Core Tip: Anaplastic thyroid carcinoma (ATC) is a rare thyroid malignancy, it is extremely aggressive and has a very low survival rate. Immunotherapy combined with targeted therapy results in prolonged survival and good quality of life. We summarize the relevant clinical data and review the literature. This report aims to provide clinical experience in the treatment of an ATC patient by immunotherapy combined with targeted therapy.